Focus: NeuroPace is a public medical device company specializing in implantable neurological treatments, particularly responsive neurostimulation (RNS) systems for epilepsy management. The company generated $80M in revenue in FY 2025 with a focused pipeline in neuromodulation.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Cooling — net -5 jobs in 30d
1 added, 6 removed. Slower than typical.
Viable for specialists seeking deep neurotech expertise in a stabilizing commercial business, but cash burn and size constraints limit upside mobility and stability.
Flagship implantable system in Phase 3-4 development with multiple trial tracks, driving commercial expansion and revenue growth.
Help build intelligence for NeuroPace
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NeuroPace's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
NPCE Explains How NeuroPace's RNS System Makes Money - MSN
NPCE Explains How NeuroPace's RNS System Makes Money MSN
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - TradingView
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now TradingView
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Yahoo Finance
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now Yahoo Finance
NeuroPace shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com Australia
NeuroPace shareholders elect directors and ratify auditor at annual meeting By Investing.com Investing.com Australia
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy - TradingView
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy TradingView
NeuroPace spotlights RNS System and new AI tool at 2026 ASSFN - Stock Titan
NeuroPace spotlights RNS System and new AI tool at 2026 ASSFN Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months.
Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy: Three-Year Efficacy and Interim Safety Results.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo